|
|
Volumn 31, Issue 1, 2008, Pages 6-10
|
|
There is a wide range of predictive dosimetric factors for I-125 and Pd-103 prostate brachytherapy
a,f
f
NONE
(United States)
|
|
Author keywords
Brachytherapy; Dosimetry; Prostatic carcinoma; Quality; Treatment margins
|
|
Indexed keywords
IODINE 125;
PALLADIUM 103;
PROSTATE SPECIFIC ANTIGEN;
PALLADIUM;
RADIOACTIVE IODINE;
RADIOISOTOPE;
ARTICLE;
BRACHYTHERAPY;
CANCER CONTROL;
CHEMICAL ANALYSIS;
CLINICAL ASSESSMENT;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSIMETRY;
FOLLOW UP;
HUMAN;
INTERMETHOD COMPARISON;
MAJOR CLINICAL STUDY;
MALE;
PRACTICE GUIDELINE;
PREDICTOR VARIABLE;
PROSTATE CARCINOMA;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT DURATION;
TREATMENT RESPONSE;
ADENOCARCINOMA;
BLOOD;
COMPARATIVE STUDY;
METHODOLOGY;
PATHOLOGY;
PREDICTION AND FORECASTING;
PROSTATE TUMOR;
RADIATION DOSE;
RADIOGRAPHY;
RISK ASSESSMENT;
SURVIVAL RATE;
ADENOCARCINOMA;
BRACHYTHERAPY;
FOLLOW-UP STUDIES;
HUMANS;
IODINE RADIOISOTOPES;
MALE;
PALLADIUM;
PREDICTIVE VALUE OF TESTS;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
RADIOISOTOPES;
RADIOTHERAPY DOSAGE;
RISK ASSESSMENT;
SURVIVAL RATE;
TOMOGRAPHY, X-RAY COMPUTED;
|
|
EID: 42449103100
PISSN: 02773732
EISSN: 1537453X
Source Type: Journal
DOI: 10.1097/COC.0b013e318068415b Document Type: Article |
|
Times cited : (10)
|
|
References (5)
|
